Average Insider

Where insiders trade, we follow

$VRDN
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Stephen F. Mahoney
CEO
143
Employees
$27.84
Current Price
$2.70B
Market Cap
52W Low$9.90
Current$27.8473.6% above low, 26.4% below high
52W High$34.29

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00---
Sells00--
2 monthsBuys00---
Sells00--
3 monthsBuys00--All Sells
Sells11$70,795.522,272
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Dec 31, 2025
Tousignant Jennifer
Chief Legal Officer
Sale2,272$31.16$70,795.52View Details
1 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
May 4, 2026
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A

Past Earnings

Historical earnings results
Feb 26, 2026
EPS
Estimated-$0.88
ActualN/A
Revenue
EstimatedN/A
ActualN/A
2 more earnings records available โ€” create a free account to see 12 months of history

Related Activity

Cross-company insider connections and cluster buy signals
Version: v26.3.23